Parotid-sparing IMRT for Nasopharyngeal Cancer

Royal Marsden NHS Foundation Trust42 enrolled

Overview

In the treatment of nasopharyngeal cancers, to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.

The purpose of this study was to determine the feasibility in delivering induction chemotherapy and concomitant chemotherapy with IMRT in the treatment of locally advanced nasopharyngeal cancers and to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Nasopharyngeal Cancers Intensity Modulated Radiotherapy With Chemotherapy

Interventions

Intensity modulated radiotherapy with chemotherapyRADIATION

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * nasopharyngeal cancers Exclusion Criteria: * Patients \<16 years old or with a previous malignancy other than non-melanomatous skin cancer were excluded

Locations (1)

The Royal Marsden NHS Foundation Trust

London, United Kingdom

Outcomes

Primary Outcomes

the incidence of ≥G2 xerostomia at 1 year using the subjective component LENTSOMA

Time frame: 12 months

Secondary Outcomes

Acute radiation toxicities

Time frame: 0-3 months

Late radiation toxicities

Time frame: 3-24 months

loco-regional disease-free survival (LRDFS), progression-free survival (PFS) and overall survival (OS)

Time frame: 2 years

chemotherapy compliance and toxicities

Time frame: 0-12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.